SunTrust analyst David MacDonald lowered his price target on UnitedHealth to $300 to reflect the compression in market multiples but also keeps his Buy rating on the company after the company’s Q1 results that were “marked by solid core trends across both divisions and a well managed medical cost trend.” The analyst notes that the industry concerns around Medicare for America and Affordable Care Act programs are weighing on the stock, but he sees “structural changes to the model as quite low” and remains “bullish” on the shares. MacDonald adds that UnitedHealth’s free cash flows remain “robust”, capital deployment opportunities are “plentiful” and its “valuation risk/reward is compelling.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.